FP6 priority
1.1.1   Genomics and Biotechnology for Health
1.1.2.2
Title of the proposal

Preparation and utilization of recombinant retrovirus vectors suitable for gene therapy of cancer
Institute
Slovak Academy of Sciences, Cancer Research Institute
Vlarska 7, 833 91 Bratislava, Slovak Republic
www.exon.sav.sk
Contact
Name:
Assoc. Prof. Cestmir ALTANER, PhD.,DSc.
Phone:
+421 2 59327260
E-mail:
exonalt@savba.sk


Research subject for a potential FP6 project

The main aim of the project is to continue in development of recombinant viral vectors suitable for human gene therapy for cancer. The vectors are tested for their efficacy in vitro and in vivo. Most vectors, which we developed and tested so far contain suicide genes (thymidine kinase of Herpes simplex virus, cytosine deaminase) and the retroviral vector with tumor suppressor gene p53. We are interested in:
  • retrovirus vectors containing gene(s) under X-ray inducible promoter,
  • testing of cancer gene therapy using combination of various retrovirus vectors
    		•


    Recent international cooperation of the research team

    Molecular Biology Unit
    Faculty of Agronomy,
    Gembloux, Belgium


    Proposerīs relevant publications related to the research subject

    Altaner C.: Gene therapy for cancer (Present status) MinireviewNeoplasma 42, 209- 213 (1995)

    Hlavaty J., Hlubinova K., Altaner C: Construction and testing of gene therapy retroviral vector expressing bacterial cytosine deaminase gene. Neoplasma, 46, 267 – 276, (1999).

    Hlavaty J., Hlubinova K., Bies J., Altaner C: Cells producing recombinant retrovirus with thymidine kinase gene from Herpes simplex virus suitable to human gene therapy for cancer. Neoplasma, 46, 329-334, (1999).

    Hlavaty J., Tyukosova, S., Bies J., Hlubinova K., Altaner C: Retrovirus vector containing wild type p53 gene and its effect on human glioma cells. Neoplasma 47, 204-211, (2000).

    Hlubinova K., Hlavaty J., Altaner C.: Human glioma cells expressing herpes simplex virus thymidine kinase gene treated with acyclovir and bromoeoxyuridine. Evaluation of their activity in vitro and in nude mice. Neoplasma 48, 398-406 (2001).